Lpath Grants Pfizer Exclusive Option for Worldwide License for AMD Treatment iSONEP
Lpath, Inc. has entered into an agreement providing Pfizer with an exclusive option for a worldwide license to develop and commercialize iSONEP Lpath's lead monoclonal antibody product candidate, which is being evaluated for the treatment of wet age-...